These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 23792410

  • 1. Fetal rat hearts do not display acute cardiotoxicity in response to maternal Doxorubicin treatment.
    Gziri MM, Pokreisz P, De Vos R, Verbeken E, Debiève F, Mertens L, Janssens SP, Amant F.
    J Pharmacol Exp Ther; 2013 Sep; 346(3):362-9. PubMed ID: 23792410
    [Abstract] [Full Text] [Related]

  • 2. A short-time model to study relevant indices of cardiotoxicity of doxorubicin in the rat.
    Hole LD, Larsen TH, Fossan KO, Limé F, Schjøtt J.
    Toxicol Mech Methods; 2013 Jul; 23(6):412-8. PubMed ID: 23379389
    [Abstract] [Full Text] [Related]

  • 3. Annexin V imaging of acute doxorubicin cardiotoxicity (apoptosis) in rats.
    Bennink RJ, van den Hoff MJ, van Hemert FJ, de Bruin KM, Spijkerboer AL, Vanderheyden JL, Steinmetz N, van Eck-Smit BL.
    J Nucl Med; 2004 May; 45(5):842-8. PubMed ID: 15136635
    [Abstract] [Full Text] [Related]

  • 4. Baicalein alleviates doxorubicin-induced cardiotoxicity via suppression of myocardial oxidative stress and apoptosis in mice.
    Sahu BD, Kumar JM, Kuncha M, Borkar RM, Srinivas R, Sistla R.
    Life Sci; 2016 Jan 01; 144():8-18. PubMed ID: 26606860
    [Abstract] [Full Text] [Related]

  • 5. Febuxostat ameliorates doxorubicin-induced cardiotoxicity in rats.
    Krishnamurthy B, Rani N, Bharti S, Golechha M, Bhatia J, Nag TC, Ray R, Arava S, Arya DS.
    Chem Biol Interact; 2015 Jul 25; 237():96-103. PubMed ID: 26036690
    [Abstract] [Full Text] [Related]

  • 6. Glutamine regulation of doxorubicin accumulation in hearts versus tumors in experimental rats.
    Todorova VK, Kaufmann Y, Hennings LJ, Klimberg VS.
    Cancer Chemother Pharmacol; 2010 Jul 25; 66(2):315-23. PubMed ID: 19898822
    [Abstract] [Full Text] [Related]

  • 7. Chemotherapy during pregnancy: effect of anthracyclines on fetal and maternal cardiac function.
    Gziri MM, Debiève F, DE Catte L, Mertens L, Barrea C, VAN Calsteren K, Han SN, Heyns L, Amant F.
    Acta Obstet Gynecol Scand; 2012 Dec 25; 91(12):1465-8. PubMed ID: 22880883
    [Abstract] [Full Text] [Related]

  • 8. Oxidative stress and myocardial gene alterations associated with Doxorubicin-induced cardiotoxicity in rats persist for 2 months after treatment cessation.
    Richard C, Ghibu S, Delemasure-Chalumeau S, Guilland JC, Des Rosiers C, Zeller M, Cottin Y, Rochette L, Vergely C.
    J Pharmacol Exp Ther; 2011 Dec 25; 339(3):807-14. PubMed ID: 21934029
    [Abstract] [Full Text] [Related]

  • 9. General oxidative stress during doxorubicin-induced cardiotoxicity in rats: absence of cardioprotection and low antioxidant efficiency of alpha-lipoic acid.
    Ghibu S, Delemasure S, Richard C, Guilland JC, Martin L, Gambert S, Rochette L, Vergely C.
    Biochimie; 2012 Apr 25; 94(4):932-9. PubMed ID: 21396425
    [Abstract] [Full Text] [Related]

  • 10. Mechanism of protection of moderately diet restricted rats against doxorubicin-induced acute cardiotoxicity.
    Mitra MS, Donthamsetty S, White B, Latendresse JR, Mehendale HM.
    Toxicol Appl Pharmacol; 2007 Nov 15; 225(1):90-101. PubMed ID: 17904602
    [Abstract] [Full Text] [Related]

  • 11. Role of exogenous melatonin in reducing the cardiotoxic effect of daunorubicin and doxorubicin in the rat.
    Dziegiel P, Jethon Z, Suder E, Sopel M, Rabczyński J, Surowiak P, Zabel M.
    Exp Toxicol Pathol; 2002 Feb 15; 53(6):433-9. PubMed ID: 11926284
    [Abstract] [Full Text] [Related]

  • 12. Over-expression of calpastatin aggravates cardiotoxicity induced by doxorubicin.
    Wang Y, Zheng D, Wei M, Ma J, Yu Y, Chen R, Lacefield JC, Xu H, Peng T.
    Cardiovasc Res; 2013 Jun 01; 98(3):381-90. PubMed ID: 23455548
    [Abstract] [Full Text] [Related]

  • 13. Comparison of doxorubicin- and MEN 10755-induced long-term progressive cardiotoxicity in the rat.
    Cirillo R, Sacco G, Venturella S, Brightwell J, Giachetti A, Manzini S.
    J Cardiovasc Pharmacol; 2000 Jan 01; 35(1):100-8. PubMed ID: 10630739
    [Abstract] [Full Text] [Related]

  • 14. PNU-159548, a novel cytotoxic antitumor agent with a low cardiotoxic potential.
    Della Torre P, Podestà A, Imondi AR, Moneta D, Sammartini U, Arrigoni C, Terron A, Brughera M.
    Cancer Chemother Pharmacol; 2001 Apr 01; 47(4):355-60. PubMed ID: 11345653
    [Abstract] [Full Text] [Related]

  • 15. Cardioprotective effect of metformin against doxorubicin cardiotoxicity in rats.
    Argun M, Üzüm K, Sönmez MF, Özyurt A, Derya K, Çilenk KT, Unalmış S, Pamukcu Ö, Baykan A, Narin F, Elmalı F, Narin N.
    Anatol J Cardiol; 2016 Apr 01; 16(4):234-41. PubMed ID: 26642465
    [Abstract] [Full Text] [Related]

  • 16. Effects of three new anthracyclines and doxorubicin on the rat isolated heart.
    Chen ZM, Colombo T, Conforti L, Grazia Donelli M, Fiedorowicz RJ, Marchi S, Paolini A, Riva E, Zuanetti G, Latini R.
    J Pharm Pharmacol; 1987 Nov 01; 39(11):947-50. PubMed ID: 2892924
    [Abstract] [Full Text] [Related]

  • 17. Biocompatible microemulsion modifies the pharmacokinetic profile and cardiotoxicity of doxorubicin.
    Assumpção JU, Campos ML, Ferraz Nogueira Filho MA, Pestana KC, Baldan HM, Formariz Pilon TP, de Oliveira AG, Peccinini RG.
    J Pharm Sci; 2013 Jan 01; 102(1):289-96. PubMed ID: 23150468
    [Abstract] [Full Text] [Related]

  • 18. Noninvasive molecular imaging of apoptosis in a mouse model of anthracycline-induced cardiotoxicity.
    Su H, Gorodny N, Gomez LF, Gangadharmath U, Mu F, Chen G, Walsh JC, Szardenings K, Kolb HC, Tamarappoo B.
    Circ Cardiovasc Imaging; 2015 Feb 01; 8(2):e001952. PubMed ID: 25657296
    [Abstract] [Full Text] [Related]

  • 19. Antioxidants and tumor necrosis factor alpha-inhibiting activity of sesame oil against doxorubicin-induced cardiotoxicity.
    Saleem MT, Chetty MC, Kavimani S.
    Ther Adv Cardiovasc Dis; 2014 Feb 01; 8(1):4-11. PubMed ID: 24441175
    [Abstract] [Full Text] [Related]

  • 20. Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings?
    Lenčová-Popelová O, Jansová H, Jirkovský E, Bureš J, Jirkovská-Vávrová A, Mazurová Y, Reimerová P, Vostatková L, Adamcová M, Hroch M, Pokorná Z, Kovaříková P, Šimůnek T, Štěrba M.
    Toxicology; 2016 Nov 30; 372():52-63. PubMed ID: 27816693
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.